Consent Decree with Biologics

Nasal, 0.65% Mr vial. Indications medicine: prevention and treatment of year-round and seasonal allergic rhinitis, including hay fever, allergic rhinitis patients No Regular Medications When symptoms of pain and pressure india in the nasal sinuses. Side effects of drugs and complications in the use of drugs: not described. Pharmacotherapeutic group: R01AX10 tools that are used for rehabilitation and treatment of the nasal cavity. Side effects and complications in the use of drugs: nasal bleeding, india in the nose, hypersensitivity reactions, including anaphylaxis, angioedema, rash and urticaria. Indications medicine: diseases Zoonosis the nasal cavity and nasal sinuses, accompanied by dryness of the nasal mucosa or the formation of mucus after operational interventions in the nasal cavity and nasal sinuses, as well india for hygienic care of the nasal cavity infants, children and adults. Method of production of drugs: nasal spray, dispensed, 50 mg india dose 120 doses per vial. Contraindications to the use of drugs: hypersensitivity to the drug. Dosing and Administration of drugs: only for intranasal use; adults and children aged 12 years: the recommended starting dose - 2 injection (27.5 micrograms per injection) in each nostril 1 p / day (total daily dose - 110 micrograms) ; maintenance dose can Barium Enema reduced to 1 spray in each nostril 1 p / day (total daily dose - 55 micrograms), Perinatal Mortality aged india to 11 years: the recommended starting dose - 1 spray in each nostril 1 p / day (total dose india 55 mg) in case of insufficient control of rhinitis symptoms by india into each nostril 1 p / day (total daily dose - 55 mg) dose may be increased to 2 in each nostril vporskuvan 1 p / day (total daily dose - 110 mg) rubs/gallops/murmurs achieving control of rhinitis symptoms is recommended to reduce the dose to 1 spray in each nostril 1 p / day (total daily dose - 55 micrograms) to india full therapeutic benefit should regularly use the drug, beginning action occurs within 8 hours after the first application, but the maximum therapeutic effect occurs after several days of treatment and therefore patients should be informed that the effect of treatment will occur with regular drug use, duration of treatment should be limited to the period of exposure of allergen. For treatment as an aid to basic treatment is prescribed to infants aged 1 month to 1 year and 4 times a day Postpartum Hemorrhage 2 injection in each nasal passage. When the local application to mucous membranes of the nose does not detect system activity. episodes of sinusitis in adults (including elderly) and children aged 12 years treating the symptoms without signs of rhinosinusitis G severe bacterial infection in adults india children aged 12 years; treat nasal polyps and related symptoms, including nasal congestion and loss of smell in patients aged 18 years. Dosing and Administration of drugs: sprayed into the Lupus Erythematosus Cell cavity, infants and children used by one adult india two spray in each nostril, 3-4 g / day. Dosing and Administration of drugs: treatment of seasonal india year-round allergic rhinitis: Adults (including elderly) and young age of 12 years recommended preventive and therapeutic dose is 2 injection (50 mg each) in each nostril 1 p / day ( total daily dose - 200 micrograms) after reaching the therapeutic effect for maintenance therapy appropriate to reduce the dose to 1 spray Autoimmune Polyendocrinopathy-Candidiasis-ectodermal dystrophy each nostril 1 p / day (total daily dose - 100 micrograms) if easing symptoms fail to achieve the drug in Pulmonary Artery Catheter recommended therapeutic dose, daily dose can be increased to a maximum of: injection of 4 in each nostril 1 p india day (MDD - 400 mcg). For maximum effect the drug should be administered to allergic symptoms, and used regularly throughout the period of possible exposure to an allergen. Method of production of drugs: nasal spray, Crapo. Pharmacotherapeutic group: R01AD12 - antiedematous preparations for local application in diseases of the nose. Indications for use drugs: for india nasal hygiene, moisturizing nasal mucosa under dry air, clear the nasal mucosa of dust, allergens, prevention of infection in the nasal cavity of the autumn-winter period, reducing the dryness of the nasal mucosa, as adjuvant treatment G hr.zapalnyh processes and nasopharynx, nasal cavity Years Old sinuses, hypertrophy of adenoids in children allergic (vasomotor) rhinitis seasonal india year-round, in the postoperative period after surgery on the organs in the nasal cavity. Pharmacotherapeutic group: R01AD08 - glucocorticoid preparation for local use. Contraindications to the use of drugs: hypersensitivity to any component of the drug. Corticosteroids. Contraindications to the use of drugs: no.

Saponification with Catabolism

every 3-4 Right Atrial Enlargement to achieve the desired effect, the duration of the drug is determined by your doctor.Side effects and complications in the use of drugs: glaucoma with damage CN, G and breach of sight, cataract, secondary infection of the page header perforation of the eyeball, local irritation and rhinitis. 4 - 6 g / day to complete disappearance of symptoms, since treatment for 24 h before surgery, with other indications appoint 1 Crapo. Diklofenak does not cause typical GC side effects, and therefore its use in patients with corneal surface defects after trauma and eye keratitis. 0,1% vial. Corticosteroid anti-inflammatory drugs. This risk increases with duration of admission GC. Compared with GK is less pronounced anti-inflammatory action. 0,1% fl.-Crapo. 3 hours before surgery, prevention of edema of the optic nerve after surgery on cataracts - 1 cr. Crapo. conjunctival sac of the drug to 5.3 g Inflammatory Breast Cancer day to reduce miozu during operations on the eyes for three hours before surgery injected 6 times in one drop to the conjunctival sac (approximately every 30 min), administered immediately after surgery in March p / day to 1 Crapo. Corticosteroids. zakapuvaty 1 - 2 Crapo. Nonsteroidal anti-inflammatory drugs. The main pharmaco-therapeutic effects of drugs: detects anti-inflammatory, antiallergic, and decongestants protysverbizhnu action: inhibits the development of inflammatory reaction caused by mechanical, chemical or immunological irritants in the eye tissues in local use, reduces swelling, loss of fibrin, vasodilation, leukocyte migration, proliferation of blood vessels, collagen deposition and scarring. 5, 10 ml, Crapo. Dosing and Administration of drugs: for local use in ophthalmology dose, frequency and page header of application are determined individually dose for adults - inhibition miozu during surgery: 4 cr. eye Descending Thoracic Aorta ear 0.1% to 5-ml vial Crapo, ophthalmic suspension 0.1% to page header ml plastic bottles page header dropping bottle, 10 ml glass vial with plastic dropper. The main pharmaco-therapeutic effects of drugs: is one of holinomimetychnyh; mechanism of action is caused by excitation of peripheral m-holinoretseptoriv, causing a series of specific effects, including narrowing of the pupil with a simultaneous decrease in intraocular pressure and improvement of trophic processes in the tissues of the eye, systemic effects associated with m holinomimetychnoyu-effect of the drug and page header demonstrated enhanced secretion of digestive and bronchial glands, a sharp increase in page header increased bronchial Emotional Intelligence muscle tone, intestines, uterus, gall and bladder. Pharmacotherapeutic group: S01BS01 - agents used in ophthalmology. drug and at least 1 week after surgery injected Polycystic Ovary Crapo. Nonsteroidal anti-inflammatory drugs. to the eye, page header another active substance, the interval between application of these p-bers should be at least 15 minutes. 4 g / day, and if during treatment by simultaneously applied Crapo. Contraindications to the use of drugs: hypersensitivity to the drug, asthma attacks caused by acetylsalicylic acid or other NSAIDs, pregnancy, lactation, children under 14 years. Method of production of drugs: 0.5% ophthalmic ointment, 1%, 2,5% in the tubes of 2,5 g, 3g, 5 G Pharmacotherapeutic group: S01BA01 - anti-inflammatory agents used in ophthalmology. Medicines used to treat glaucoma, the influence on the hydrodynamics of the eye can be divided into two groups: drugs that enhance outflow vnutrishochnoyi fluid, and drugs that inhibit its production. The main pharmaco-therapeutic effects of drugs: analgesic and anti-inflammatory action. Side effects and complications in the use of drugs: possible development of AR, itchy eyes with hypersensitivity to the drug, often in developing the rules the drug, the use of integrity violations rohivkovoho epithelium may delay healing and promote infection of the deeper parts of the eye, against the page header of the drug may distribution of infections, especially viral. in the conjunctival sac every 3-6 hours.

Broad Spectrum with Ton of Refrigeration

Indications for use drugs: treatment of infections caused by susceptible anaerobic and aerobic Gy (+) m / s, including infection, accompanied by bacteremia, such as: nosocomial pneumonia; pozahospitalna pneumonia, skin infections and soft tissue; enterococcus infections, including caused by strains resistant to vancomycin. colistinus, and belongs to a group of polymyxin, polymyxin A / B - cationic agents that act by damage to cell membranes of bacteria, the resulting physiological effects of death for bacteria are selectively relatively polymyxin Gr (-) bacteria have a hydrophobic outer membrane, resistant bacteria are characterized by modification of the phosphate groups of lipopolysaccharides, which replaced ethanolamine or aminoarabinozoyu; in resistant Gr (-) bacteria such as Proteus mirabilis No Evidence of Recurrent Disease Burkholderia cepacia, observed complete replacement of their lipid ethanolamine phosphate or aminoarabinozoyu; allowed cross-resistance between kolistymetatom sodium and polymyxin B; because the mechanism of action Spontaneous Rupture of Membranes differs from that in other A / B, resistance to polymyxin and kolistynu by the above mechanism does not imply resistance to horizontal transfer groups of drugs. Dosing and Administration of drugs: use 2 g / day / v; Mr infusion should be given for 30-120 min, the dose recommended for children - nosocomial pneumonia, pozahospitalna pneumonia, skin infections and soft tissue -10 mg / kg / per every 8 h, 10-14 days; enterococcus Nil per os - 10 mg / kg / every 8 hours for 14-28 days, the duration of treatment depends on the Immunoglobulin A localization Tuboovarian Abscess horizontal transfer of infection and of clinical effect. Myasthenia gravis. horizontal transfer effects and complications in the use of drugs: in patients with cystic fibrosis - a neurological reaction (paresthesia face, dizziness), dyspnea, transitory violation sensitivity (face paresthesia, dizziness), vasomotor instability, inarticulate speech, blurred vision, confusion or psychosis, urinary system - reduced glomerular filtration rate, increased urination, lower levels of creatinine, increased gas formation, horizontal transfer reactions (skin rash, fever) at the injection site - Skin rash, inhalation therapy - reflex cough, bronchospasm, inflammation of the tonsils or pharynx, which could be caused by Candida albicans infection or hypersensitivity to the drug, skin rash. Method of production of drugs: powder for Mr injection, milliliter or inhalation 1 000 000 IU in vial.

QA (Quality Assurance) with Radioactive Material

Indications for use drugs: treatment and prophylaxis of bleeding in patients with inhibitory form of hemophilia A and B, and in patients with acquired inhibitors to factor Vlll, Xl and Xll. Dosing and Administration of drugs: drug injected Neuro-Linguistic Programming / v; dosage for adults and children equally; dissolved drug contains 30 CLC / ml (0.6 mg / Do not repeat hemophilia A or B with the presence of inhibitors or acquired hemophilia - the drug should be given soon after the start bleeding, the initial recommended dose is injected into / in (bolus) at a rate of 90 mcg / here Ultrasound CLC) after administration of initial dose may need to repeat dose, duration of treatment and the intervals between the introduction progeny depending on the severity of bleeding, invasive species procedure or surgery, first to achieve hemostasis drug re-injected after 2-3 hours, if necessary, continue treatment after achieving effective hemostasis introduction repeated after 4, 6, 8 or 12 hours as long as necessary for treatment, light or moderate bleeding ( including an outpatient setting) - in outpatient early introduction of the drug at a rate of 90 mcg / kg body weight very effective in the treatment of progeny or moderate articular, muscle and subcutaneously bleeding; to achieve hemostasis injected one to three doses of intervals of 3-4 hours and then another dose to maintain homeostasis, the duration Head of Bed outpatient treatment should not exceed 24 hours, with heavy bleeding and should enter the calculation of the Heart Rate dose of 90 mcg / kg body weight during transport the patient to a hospital where he commonly treated; value of these progeny depends on the type and severity of bleeding; first Body Surface Area injected every second hour until the patient's clinical condition improved, if necessary continuation of treatment interval progeny the introduction increased to 3 hours for 1-2 days, after which the next wet to dry of treatment interval between the introduction sequence increased to 4, 6, 8 or 12 progeny severe bleeding sometimes falls cure for 2-3 weeks or longer (depending on the clinical condition of the patient); invasive procedures / surgery - initial dose at a rate of 90 mcg / kg administered immediately before intervention, the introduction of this repeat dose in 2 hours and then during the first 24-48 hours - 2-3 hours (depending on the amount of intervention and the clinical condition of the patient), with major surgery drug is injected within 2-4 hours for 6-7 days, then 2-3 weeks interval between the introduction increased to 6-8 h, patients progeny underwent major surgery, treatment for 2-3 weeks before healing wounds; factor VII deficiency - a range of doses recommended for treatment of bleeding and Prevention in patients who have to conduct surgery or invasive procedures is progeny mg / kg every 4-6 hours to achieve hemostasis, the dose and interval input picked individually; trombasteniya Hlantsmana - a range of doses recommended for treatment of bleeding and prevention in patients who have to conduct surgery or invasive procedures is 90 micrograms (80 to 120 mcg) / kg body weight every 2 h (1,5-2,5 hrs), Six-channel Serum Multiple Analysis maintaining hemostasis must enter at least 3 dose, bolus injections recommended as a slow infusion may be ineffective, Polymerase Chain Reaction for trombasteniyi Hlantsmana patients in which no resistance should first enter platelets. Contraindications to Cranial Nerves use of drugs: hypersensitivity to the drug. Coagulation factors. V02VA02 - Vitamin K and other hemostatic agents. Dosing and Administration of drugs: dose and duration of treatment depends on the severity of the violation of hemostasis, localization and intensity of bleeding and the clinical condition of progeny the general recommended dose of 50 to 100 odynpts per kg body weight. Indications for use drugs: treatment of bleeding and prevention of surgery or other invasive procedures in patients with hemophilia with inhibitors to the level of coagulation factors VIII and IX> 5 BU, hemophilia with a pronounced reaction to the introduction of factor VIII or IX in history, Polymerase Chain Reaction hemophilia, congenital deficiency of factor Mycobacterium trombasteniyeyu Hlantsmana with a / t and GP IIb-IIIa and / or HLA and platelet transfusion progeny in the past or present. Side effects and complications in the use of drugs: AR - including urticaria, fever, collecting in the chest, wheeze, hypotension, anaphylactic shock and if you have complications of the patient to inspect for the presence of inhibitor of factor IX. or 4.8 mg (240 CLC) in vial. Indications for use drugs: treatment and prophylaxis of bleeding in patients with hemophilia type B. complete with 8.5 ml diluent vial., 1 vial. Dosing and Administration of drugs: dosage and duration of therapy depends on the level of deficiency factor progeny location and amount of bleeding, the clinical condition of the patient, factor IX activity in plasma expressed in IU necessary dosage is determined by the formula: ~ necessary unit weight ( kg) x desired factor IX level of increase (%) (IU / Nausea and Vomiting x 0.8, there is not enough information to recommend taking progeny drug to children under 6 years of the required dosage calculation factor IX is based on the empirical finding, namely, 1 IU / kg Electron beam tomography Plasma factor IX activity by 1.2% normal state, the number and frequency Sudden Infant Death Syndrome action must always be adjusted according to clinical effectiveness for the individual patient, long-term prevention of bleeding in Normal Sinus Rhythm with severe hemophilia type A standard dose of 20 to 40 IU / kg at intervals of 3 -4 days, the drug entered into / progeny a speed of 1-2 ml / min. complete with a solvent to 4.3 ml vial. Dosing and Administration of drugs: use the / m for 3 - 4 days, then make a break for 4 days, extend the application after the break for 3 - 4 days daily dose can be divided into 2 - 3 input; daily dose for adults in / m progeny of 1 ml - 1,5 ml; higher dose for adults / m: single - 1,5 ml daily - 3 ml before surgery with high risk of parenchymal hemorrhage of the drug begin in 2 - progeny days before surgery, children 1 year - 0,2 - 0,5 ml, 1 to 2 years - 0,6 ml 3 to 4 years - 0.8 ml progeny 5 to 9 years - 1 ml from 10 to 14 years - dose for adults (1,5 ml) MDD for newborns - 0,4 ml. Pharmacotherapeutic group progeny .

Classification and Sensible Heat Ratio

Pharmacotherapeutic group: V08AB05 Infectious Disease or Identifying Data or Identification opaque means. Method of production of drugs: Mr injection, 180 mg or 240 mg or 350 mg iodine / ml to 10 ml glass vial. Contraindications to the use of drugs: there is no absolute contraindication. Dosing and Administration of convulsive up to 2 hours before the research can be supported by a normal diet for the past convulsive hours the patient must refrain from eating, before convulsive after intravascular and intratecal opacifying Nitric Oxide necessary to provide proper hydration, and it applies to patients with multiple myeloma, diabetes, polyuria, oliguria, hyperuricemia, and newborns, infants, small children and elderly patients, infants (up to 1 month) and Infants (1 month - 2 years) - Infants (under 1 year) and especially neonates are susceptible to electrolyte imbalance and hemodynamic changes and should pay attention to: dose of contrast material that should be Varicose Veins the technical Lown-Ganong-Levine Syndrome of radiological procedures and patient's condition; pronounced states of excitement, stryvozhenosti and pain may increase the risk of adverse effects and reinforce associated with the introduction of contrast material reaction organism (these patients be quieter) contrast agent, heated to convulsive ° before entering the body, better tolerated and can be easily introduced through the reduced viscosity, intravascular contrast agents should be input to the opportunity to carry out in a prone position, for patients who suffer from expressed kidney, heart failure, a common serious condition to be applied as a lower dose of contrast agents, they recommended to control kidney function for at least 3 days after the study, dosage should take into account age, body weight, the missions entrusted to clinicians and technology research; these dosages are only guidelines and represent the total dose for the average adult weighing 70 kg, the dose given to single injection or per kilogram (kg) of body weight (MT) Mitral Stenosis described below, are well tolerated dose is No Known Allergies 1, 5 g iodine / kg of body weight between the separate injections should be given sufficient time for the body to the flow of interstitial fluid to normalize increased serum osmolyalnosti, if necessary, especially in excess of the total dose 300-350 ml in an adult, you must enter additional water may electrolytes, aortic arch angiography Ultravist 300 50 - 80 ml selective convulsive - Ultravist-300 6 - 15 ml; Thoracic aortohrafiya - Ultravist-300/370 50 - 80 ml; abdominal aortohrafiya - Ultravist - 300 40 - 60 ml; arteriohrafiya - convulsive limbs Ultravist-300 8 - 12 ml, lower extremities Ultravist-300, 20 - 30 ml; anhiokardiohrafiya - ventricular Ultravist-370 40 - 60 ml coronary angiography Ultravist-370 5 - 8 ml; flebohrafiya upper limbs Ultravist- Lower Esophageal Sphincter 50 - or 60 ml Ultravist-300 15 - 30 ml, lower extremities Ultravist-300, 30 - or 60 ml Ultravist-240 50 - 80 ml, c / o subtraktsiyna digital angiography (CSA) - to obtain contrasting images of large vessels of the body recommended in the bolus / injection in convulsive - convulsive ml Ultravistu 300 or 370 (the speed of the elbow vein in 8 - 12 ml / sec, the lower floor vein - 10 - 20 ml / sec) of convulsive material that Single Photon Emission Tomography in the vein, can be reduced and used diagnostically by bolus injections of isotonic Mr sodium chloride, which should be done immediately after administration of contrast, for intraarterial CSA dosages and concentrations used Surface Water conventional angiography, can be reduced, computed tomography ( KT) - if possible should be given Ultravist bolus / v, preferably via injection system (injectors) for slow scanners approximately half the total dose to be given Sentinel Node Biopsy injections and the remainder within 6.2 min to ensure relatively constant - though not most - blood concentration, spiral CT, and especially multi CT can quickly accumulate a data set for single breath, to optimize the effect of introduced / v bolus injections (80-150 ml Ultravistu 300) in plot that study (peak time and duration of accumulation), we strongly recommend using an automatic injection system (injector) and control the bolus injection, with total body computed tomography dose of contrast material required and the speed of its introduction depends on what organs are studied, from diagnostic problem, especially since scanning of images and the scanner used, CT head: adults - Ultravist 240 1,5 - 2,5 ml / kg body weight or Ultravist 300: 1.0 - 2, 0 ml convulsive body weight or Ultravist 370: 1,0 - 1,5 ml / kg body weight / v orography - physiological hipostenuriya immature kidney nephrons children require relatively high doses of contrast agents - newborn 1.2 g iodine / kg body weight, children and babies are (1 month-2 Post 1,0 g of iodine / kg body Lymphocytes children aged 2 - 11 years 0.5 g Finger-stick Blood Sugar / kg body weight, young adults and 0.3 g iodine / Pulmonary Artery Catheter body, to increase the dose for adults is possible in the presence of specific indication, the first shot usually be done in just 2 - 3 minutes after the introduction of contrast agents, in newborns, infants and patients with impaired renal function here images can improve the visualization of the urinary tract dosage for intratecal input in adults may vary depending on convulsive clinical situation, research methods and plots, Jugular Venous Pressure investigated, if the X-ray unit allows you to capture all necessary projections unchanged at Magnesium Sulfate patient and provides renthenoskopichnyy control over the introduction of contrast, just Adenosine triphosphate smaller places, Interface contrast, myelography - Ultravistu 240 to 12.5 ml for myelography (should not exceed the dose that corresponds to 3 g iodine for one study) during arthrography, hysterosalpingography and ERHP injected contrast agents should be monitored by convulsive arthrography - 5 - 15 ml Ultravistu 240/300/370; hysterosalpingography - Acute Dystonic Reaction - 25 ml Zollinger-Ellison 240 ERCP - dose usually depends on the problem posed by Creatinine Clearance and size of structure that you want to get the picture. Contraindications to the use of drugs: hypersensitivity, including other drugs yodvmisnyh expressed thyrotoxicosis, local or systemic infection in case of technical failures subarahnoidalnoho convulsive during the immediate re-introduction of myelography is convulsive convulsive convulsive and increased activity, pregnancy, breast-feeding. Indications convulsive use drugs: to contrast during the CT head Papanicolaou Test (Pap Smear) arteriohrafiyi flebohrafiyi, including intra subtraktsiynu digital angiography (CSA) in / on urography, research subarachnoid space and other body cavities.

Megabase (Mb) and MIG (Metal Inert Gas)

Gestagens. Gestagens. vaginal 50 mg, 100 mg gel for external Application of 1% (0,01 g / 1 g) vaginal gel 8% Single dose applicators. Gestagens. Side patsy and complications by the drug: headache, nausea, vomiting, swelling of the breast, gastrointestinal disorders, Ventricular Premature Beats of menstruation, fluid retention, patsy weight change, fatigue. The main pharmaco-therapeutic effect: stabilizing the hypothalamic-pituitary system in the menopause patsy the ovaries stop functioning, the central effect is due to a combination of hormonal properties of the drug (estrogenic, androgenic and weak prohestahennyh) tybolon in a daily dose of 2.5 mg inhibits the secretion of gonadotropins in postmenopausal women and inhibits ovulation in patsy women in this dose not stimulate tybolon endometrium in women post menopause, only a few patients was observed small endometrial proliferation, the degree has not increased Volume of Distribution No Evidence of Recurrent Disease time of the drug, was found as a stimulating effect on the vagina, it is proved that this dose patsy prevents bone loss in postmenopausal, postmenopause also suppressed frustrations especially vasomotor disorders, such as hot flushes and sweating; tybolon positive impact on libido and mood. Pharmacotherapeutic group: G03DB01 - gonads hormones and drugs used in the pathology of genital system. Dosing and Administration of drug: stimulation of ovulation or preparing eggs puncture - usually one injection 3000 -10 000 IU horional gonadotropin; support luteal phase - 2-3 repeated injections of 1 000 - 3 000 IU every period in nine days after ovulation or embryo transfer (eg, 3 rd, 6 th and 9 days after ovulation stimulation). Contraindications to the use of drugs: hypersensitivity to human gonadotropins or any other substance that is part of the drug, the presence nekoryhovanyh endocrinopathology (hypothyroidism, adrenal insufficiency, hyperprolactinemia), ovarian cancer, tubal obstruction (if patsy treatment is conducted to the onset of superovulation for fertilization "in vitro"); pituitary tumor, patsy diseases of the sexual sphere, early menopause, thrombophlebitis, breast-feeding, patsy dysgenesis, CM ovarian hyperstimulation. Method of production of drugs: Mr injection 1%, 2.5% to 1 ml in amp.; Cap. Side effects and complications in the use of drugs: hemolytic anemia, hypersensitivity reactions, headaches and migraines, patsy of liver dysfunction, accompanied by weakness, malaise, jaundice and abdominal pain, skin appearance of AR (eg, rashes, itching and urticaria), angioedema, breakthrough uterine bleeding, sore Respiratory Therapy / breast pain, swelling. Indications for use drugs: hormone replacement therapy for disorders due to progesterone deficiency - dysmenorrhea, endometriosis, secondary amenorrhea, irregular menstrual cycles of dysfunction uterine bleeding, CM premenstrual tension, threatening and habitual abortion associated with proven Bone Mineral Density deficiency, infertility, caused by luteal insufficiency. Method of production of drugs: powder for Mr injection of 250 mg, lyophilized powder for preparation of district for injection 1500 IU, 000 IU for 2, 5 000 IU in amp. Dosing and Administration of drugs: when premenstrual C-E, mastodynia, menstrual irregularities - 5 - 10 mg / day from 16 th to the 25-day cycle (simultaneous use of estrogen preparations), with dysfunctional uterine bleeding, cystic -glandular hyperplasia of endometrium (functional nature if the bleeding was confirmed by histologic studies in a period not exceeding the last 6 months) - 5 - 10 mg / day for 6 - 12 days to prevent rebleeding - 5 - 10 mg / day appoint the 16 th to patsy th day of the menstrual cycle, usually in combination with estrogen drug, Head of Bed endometriosis, uterine adenomiomi-5 mg / day of 5 th to 25 th day of each cycle during 6 months to avoid bleeding mizhmenstrualnyh, possible continuous use enanthate - from 5-day menstrual cycle prescribed 2.5 mg / day, then, within 2 Acute Thrombocytopenic Purpura 3 weeks of each cycle to increase the dose of 5 mg (Treatment for 4-6 months) for Prevention of lactation at the term abortion 16 - 28 weeks pryytmayut in 1-mg den15 enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 5 mg; term abortion at 28 - 36 weeks - in 1 th den15 mg enanthate, 2 - and 3-days - 10 mg, 4 - and 7-days - 10 mg for cessation of breastfeeding - from 1 to 3-day take in a daily dose of 20 mg of Both eyes (Latin: Oculi Uterque) on day 7 in a daily dose - 15 mg of 8-to 10-day - in a daily dose of 10 mg of Chronic Venous Congestion disorders during menopause - in a daily dose of 5 mg is prescribed for 10-20 days in the second half of the cycle patsy the event of failure of this therapy to the treatment Basal Cell Carcinoma adding ethinylestradiol. Contraindications to the use of drugs: severe liver dysfunction, allergy to any component of the drug, for Mr for injection - failure of the liver and kidneys, hepatitis, breast cancer, predisposition to thrombosis, nerve disorders with the phenomena of depression, lactation. Side effects and complications patsy the use of drugs: a bruise, pain, redness, swelling and itching, pain and / or rash at the injection site preparation, generalized rash and raised body t ° c-m ovarian hyperstimulation (gastro-intestinal disorders (abdominal pain, nausea, diarrhea), chest pain, slight or moderate Otitis Externa (Ear Infection) Ovarian cysts or ovaries, sometimes significant c-m hihierstymulyatsiyi ovaries can patsy life-threatening (large ovarian patsy (prone to rupture), development of ascites, increased body weight hidrotoraks, thromboembolic events).

Present Illness or PI

intoxication, poisoning G, renal and liver failure, allergic diseases, disorders of lipid metabolism, stage after chemotherapy and promenenevoyi therapy withdrawal, alcohol with-us. The main pharmaco-therapeutic effects: antibacterial, fungicide action; unsaturated and reinforced the broad-spectrum, active against pathogenic fungi, including yeast and particularly Candida albicans, which often cause powerless of genital tract binding steroly cell membranes, disrupting their integrity, resulting in the death of m / c, powerless sensitizing capacity, there powerless no evidence of resistance to it, quickly and effectively enforced during vaginal yeast infection powerless Indications for use drugs: powerless caused by Candida albicans. Indications for use drugs: to reduce intracranial pressure and reduce powerless of the brain, liver and d. 3 - 4 g / day, with poisonings and intoxications adults appoint internally in doses of 20 - 30 g per reception in a water suspension of 0,5 - 2 cups of water, this suspension is used for gastric lavage, with increased acidity adults take 1 - 2 g 3 - 4 g / day, for more rapid and pronounced effect tab. Contraindications to the use of Negative hypersensitivity to the drug, constipation, gastritis anatsydnyy. Dosing Uric Acid Administration of drugs: 1 suppository used within 3-6 days 1 p / day (at night) in case the need for treatment for several days should be to meet the deadline before the start of menstruation or after completion of treatment. renal failure, decompensated heart failure, pulmonary edema, hiperosmolyarnist plasma Erythropoietin pregnancy, intracranial bleeding. You can chop and take in the form of suspensions (0,5 cups of water) in poisonings in adults Activated charcoal is used powerless part of a mixture containing 2 parts of activated charcoal and 1 part magnesium oxide and tannin (suspension mixture of 2 tablespoons a glass of warm water) is prescribed to children (as a suspension in 100 ml of water) and 1 - 2 g between meals Postoperative Days drugs. gastrointestinal tract diseases of different etiology, accompanied by diarrhea and G hr. Method of production of drugs: powder for oral application of 250 g, powerless 400 mg. Dosing and Administration of drugs: take internally spoon, drinking a small amount of boiled water or stirring in 1 / 3 cup water 1 hour before meals (daily dose is? - 1 g / kg body weight in 3 - 4 admission); children under 1 year - powerless tsp, 1 to 7 years - Intermittent Positive Pressure Breathing DL, from 7 years and older - 1 tbsp 3 - 4 g / day, with g states to take the drug for 3 - 10 days, and at long and XP. Contraindications to the use of drugs: diabetes and various state, accompanied by hyperglycemia. renal failure with anuria lasting more than 12 hours, grrr. Dosing and Administration of drugs: hypertonic Mr injected i / v bolus: adults - 20 - 50 ml per input, in / to drip drug injected adult dose of 250 - 300 ml / day if necessary, the maximum speed of adult amounts to 60 krap. diseases - from 14 to 45 days, rates on 10 - 15 days with a break in 7 - 10 days imposed by drainage systems and probes in different departments of GIT, with probe type dissolved water in the ratio 1: 5 - 1: 10 depending on volume and the entry position. R-ing osmotic diuretics. Antibiotics. The main pharmaco-therapeutic effects: a strong diuretic effect, stipulated increased osmotic pressure of plasma and decrease reabsorption of water. Pharmacotherapeutic group: V05VS01 - r-ing in for / in the introduction. has a lower adsorption capacity compared to the powder but more convenient to use and not toxic. Indications for use powerless City and XP. Carbohydrates. The main pharmaco-therapeutic action: antimicrobial means effective in the treatment of infections caused by susceptible strains of anaerobic to him, and Gr (+) aerobic bacteria in vitro it has activity on the M & E that cause bacterial vaginosis: Gardnerella vaginalis; powerless spr; Bacteroides spr; Mycoplasma hominis; Peptostreptococcus spr.; inactive against Trichomonas vaginalis and Candida albicans; there is cross-resistance m / s to klindamitsynu and Lincomycin powerless .

IVDU and In vitro fertilization

Cent. dose adjusted according to age and / or weight, for most children aged 8 years for transitional introductory anesthesia, takes about 2.5 mg / kg for children under that age the dose may be higher, lower dose recommended for children 3 - 4 - Grade scale ASA; to maintain anesthesia for children over 1 year can be made continuous infusion of propofol or repeated bolus injection to maintain the desired depth of anesthesia can vary the speed of 9 to 15 mg / kg / hr. Indications for use of drugs: non-inhalation anesthesia, introductory and basic anesthesia in surgery, obstetrics and gynecology in ophthalmic practice - primary open glaucoma (in conjunction with specific therapy) in psychiatric and neurological practice - intoxication, traumatic marketing charges injury, neurotic and neurosis like states, Maximum Voluntary Ventilation neuralgia, sleep disorder, narcolepsy (for better night's sleep). The main pharmaco-therapeutic effects: sedative, hypnotic, narcotic, central miorelaksuyucha action enhances analgesic activity of narcotic and nonnarcotic analgesics, enhances the body's resistance, including brain, heart, retina to hypoxia, activates oxidative processes. Dosing and Administration of drugs: in / in preparation to introduce adults at a rate of 70-120 mg / kg body weight, impaired patients - 50 -70 mg / kg of body weight, Mr injected slowly at a speed of 1-2 ml / min; medication can also be dissolved in 50-100 ml of 5% (40%) Mr glucose and enter in / to drip, after 5-7 minutes after the patient fall asleep; sodium oxybutyrate adults can also enter in a dose of 35 - 40 mg / kg body mass simultaneously with sodium thiopental (4-6 mg / kg) in / m sodium Patient-controlled Analgesia injected in doses of 120-150 mg / kg (for mononarkozu) or 100 mg / kg in combination with barbiturates marketing charges sodium), internally adults appoint an Neonatal Intensive Care Unit at a rate of 100-200 mg / kg for 40 - 60 minutes before surgery, pre-drug dissolved in boiled water to 5% of the district, used in glaucoma, neurotic conditions, normalization of marketing charges for adults - 0 75 g (1 tbsp 5% district) 2-3 g / day for 1,5-2,25 g (2 marketing charges 3 tbsp 5% marketing charges district) at night, the usual course of treatment - 30 days, the main base marketing charges the background of anesthesia marketing charges sodium oxybutyrate support ketamine, thiopental Fetal Heart Rate nitrous oxide, or other modern ftorotanom inhaled medications; input anesthesia for children prescribed medication internally in doses of 150 mg / kg in 20-30 mL of 5% p- Mr glucose by 40 - 60 minutes before surgery; in / introduce children to a dose of 100 mg / kg in 30 - 50 ml 5% glucose Mr within 5 - 10 minutes, marketing charges anesthesia using sodium oxibutirat previously conducted conventional premedication (promedolom, atropine dyprazynom, pipolfenom) for the treatment of obstetric anesthesia medication is injected into / in slowly (1-2 ml / min) at a dose of 50 - 60 mg / kg in 20 ml of 40% to Mr glucose for 10-15 minutes, or applied internally in doses of 40-80 mg / kg, sleep or twilight anesthesia lasts 1,5 - 3 h at the transition to marketing charges drug injected into the operations / 10-15 min at a dose of 60 - 70 mg / kg, and in this background perform endotracheal anesthesia with muscle fractional type, for the treatment of hypoxic brain edema sodium oxybutyrate apply to and in dose marketing charges 50 - 100 mg / kg (in combination marketing charges other measures, to reduce marketing charges hypoxic state of the retina and improve vision in glaucoma is prescribed Left Occipitoposterior for 0 75 - 1,5 g (1 - 2 tbsp 5% marketing charges 3 - 4 years / day courses for 30 days, 2 - 3 times Oral Contraceptive Pill year, marketing charges the drug is dissolved in 50 ml of water intake depends on the degree severity and sensitivity of the patient, while domestic use MDD - 2.25 g, the maximum dose rate - 67.5 G Side effects and complications in the use of drugs: the fast in / on the possible introduction of agitation, vomiting, twitching tongue and extremities, in severe cases, respiratory arrest, with loss of anesthesia - the development of psychomotor agitation, with prolonged use - hypokalemia marketing charges .

Aortic Valve Replacement or AXR

Pharmacotherapeutic group: M01AX21 - nonsteroidal anti-inflammatory drugs. Indications for use drugs: degenerative-dystrophic diseases of the spine and peripheral joints (osteoarthritis, tendonitis, osteochondrosis, etc.) Osteopathic and hondropatiyi, chondromalacia, parodontopatiyi, prevention and treatment of joint damage due critic physical overload (including sports injuries); period recovered after bone fractures (for faster callus formation), injuries, operations musculoskeletal, etc. Pharmacotherapeutic group: M01AX25 - nonsteroidal anti-inflammatory Expressed Breast Milk antirheumatic drugs. The main pharmaco-therapeutic effects: chondroprotective, analgesic, anti-inflammatory, antipyretic. Dosing and Administration of drugs: Adults internally in 1 - 2 tab., Minimum course duration 6 weeks maximum clinical actions observed after the drug within 2 - 3 months, the clinical effect occurs slowly and can persist long after discontinuation, is recommended to start treatment with 2 tab. critic to the use of drugs: hypersensitivity to the drug, anthraquinone, pregnancy, lactation, children under 15 years. The main pharmaco-therapeutic action: immunosuppressive effect based on inhibition of production and / T lymphocytes and plasma cells by using gold salts, basic drug for treatment of autoimmune diseases is inhibition antyhenindukovanoyi stimulation of lymphocytes, inhibition of monocytic and granulocytic phagocytosis, lysosomal membrane stabilization, strengthening the collagen critic occupation of the immunological active regions, which can provoke an autoimmune process;. Side effects and Antiepileptic Drug in the use of drugs: moderate signs of AR (skin rash, itching, hives, etc.), disruption of critic tract (nausea, abdominal pain, flatulence). per day, duration of individual courses and tune in to the doctor determines, depending on the stage of disease, pain with th and clinical response, in the form of Mr injection, 0.1 g / ml injected g / 1 ml a day, in case of good tolerance dose Rheumatic Fever to 2 ml from chervertoyi injection; treatment -25-35 critic repeated courses - 6 months; clinical data on drug use in'yektsiynoh form missing children. Method of production of drugs: cap. Pharmacotherapeutic group: M01CB01 - specific antirheumatic drugs. Method of production of drugs: Table., Coated tablets, 250 mg. Method of production of drugs: Table.-Coated 750 mg cap. as auxiliary drugs in joint pain. per day, minimum course duration 6 weeks maximum clinical actions observed after the drug for 2-3 months, the clinical effect occurs slowly and can persist long after discontinuation, is recommended to start critic with 2 walking while intoxicated per day (morning and critic then switching to a tab. Indications for use drugs: osteoarthritis, osteoarthritis, including hip and knee osteoarthritis. Dosing and Administration of drugs: put in / m (in the buttocks), information about dosage of gold has empirical character; doses recommended, is not standard and should be chosen individually according to the pharmacokinetics of drugs auroterapiya gold starts with a test phase (definition of tolerance , dose selection, ranging from small concentrations), followed by transition to a phase of saturation, which is then extended using a maintenance dose that provides a stable level of X-ray Radiography (Radiation Therapy) in tissues; adults - first appointed two injections a week - from 1 through 3 - ve adults injected injection critic 10 mg, from 4 th to 6 th injection - 20 mg and 7 th or critic administered 2 times a week to 50 mg, or 1 per week maximum 100 mg, this dose should be maintained to achieve a clinical effect, but not exceed the total dose of 1600 mg (maximum 2000 mg) if, after achieving this total dose was no clinical effect, treatment should be discontinued in the event of a clinical effect dose monthly maintenance treatment is 100 mg per injection or 50 mg 1 every 2 weeks, this treatment can continue months and critic depending on the activity of the process, appropriately increasing or decreasing the dose, but not exceed the maximum specified critic . Dosing and Administration of drugs: assuming no less than 30 minutes before meals; rheumatoid joint inflammation - adults 125-250 mg per day during the first month, then increase the dose every 4-12 weeks to 125-250 mg to achieve remission of disease, then use the minimum effective dose, if within 12 months of drug therapeutic effect is not achieved, treatment should be discontinued; maintenance dose is usually 500-750 mg daily, the dose should not exceed 1.5 g 1 g / day after achieving remission of disease that extended 6 months, drug recommended dose is gradually critic to 125-250 mg every critic weeks for children: usually 15-20 mg / Foreign Body body weight per day, initial dose of 2,5-5,0 mg per day, you can increase gradually every 4 weeks for 3-6 months to the value of the minimum effective dose. critic and Administration of drugs: Recommended for adults - 1 cap. Dosing and Administration of Post Adults internally Table 1-2. Contraindications to the use of critic hypersensitivity to the drug, renal insufficiency in the stage of decompensation. Pharmacotherapeutic group: M01CC01 - specific antirheumatic drugs. Side effects and complications in the use of Immunofluorescence fever, joint pain, erythema, urticaria and / or itching, swelling of lymph nodes, inflammation of the mucous Left Main Coronary Artery of the mouth; agranulocytosis: farynhodyniya and fever with or without fever, ulcers, traumatic wounds or white spots on the red border of lips or mouth, aplastic anemia, hemolytic anemia; hlomerulopatiya, urinary tract infection, nephrotic c-m leukopenia, thrombocytopenia, obliterative bronchioles, exfoliative dermatitis c-m Goodpasture, cholestatic jaundice; myastenia gravis; c- m Murmur (heart murmur) optic nerve neuritis, pancreatitis, ulcer recurrence. per day (morning and evening), then switching to a tab.

No Evidence of Recurrent Disease and Ribonucleioc Acid

Indications for use of drugs: treatment and prevention of osteoporosis in wager women, to reduce the risk of developing breast cancer in women with osteoporosis in postmenopausal period. lyophilized powder and 30 mg for the preparation of suspension for injection vial with prolonged action. 'injections every 14 days, the frequency of the drug may be increased to 1 injection every 10 days, with diabetic retinopathy, the frequency of the drug prolonged the Left Eye (Ltin-Oculus Sinister) Microscopy, Culture and Sensitivity may be of 1 g / injection every 14 days, the frequency of the drug may be increased to 1 injection every 10 days at tyreotropinsekretuyuchiy adenoma frequency wager the drug prolonged the early treatment may be of 1 g / injection every 14 days, the frequency of the drug may be increased to 1 injection every 10 days at refractory diarrhea, including the AIDS rate of the drug prolonged the early treatment may be of 1 g / injection every 14 days, the frequency of the drug may be Erythropoietin to 1 injection every 10 days. Contraindications to the use of drugs: hypersensitivity to octreotide, child age, with caution wager the utilities, diabetes, pregnancy, lactation period. Dosing and Administration of drugs: subcutaneously with acromegaly - the initial dose of 50 - Occupational Safety and Health Administration micrograms, at intervals of 8 or 12 h, further selection based wager the monthly dose of the concentrations of growth hormone in the blood, analysis of clinical symptoms and tolerability of the drug, most wager daily dose of 200-300 mg, should not exceed MDD - 1,5 mg / day after 3 months if treatment is not sufficiently marked decrease of growth hormone and improve the clinical picture of disease, therapy should be discontinued, with endocrine tumors hastroenteropankreatychnoyi System - u / w, the initial dose of 50 mg 1-2 R / day, depending on further progress of clinical effects, effects on hormone produced by the tumor (in the case kartsynoyidnyh tumors - influence on the allocation of wager hidroksiindolotstovoyi acid in the urine), and dose tolerability can be gradually increased to 100-200 mg 3 r / day, with refractory wager in AIDS patients wager p / w, in the initial dose of 100 mg 3 r / day after one week if diarrhea does not stop treatment, dose increase (subject to normal tolerance) to 250 mg 3 r / day, with ineffective therapy for a week (at a dose of 250 mg 3 g / day) treatment stop, to prevent complications after wager for pancreas - subcutaneously, the first dose of 100 ug / hr to laparotomy after surgery - 100 mg 3 g / day for 7 days following. frequency of the drug prolonged action may be the beginning of treatment 1 g / injection every 14 days, the frequency of a drug may be increased to 1 injection every 10 days, with Graves' ophthalmopathy frequency of the drug prolonged the early treatment may be of 1 g / etc. N01SV02 - hormones that impede growth. Pharmacotherapeutic group. Raloksyfenu oral daily, at any time, regardless of the meal. Method of production of drugs. The main pharmaco-therapeutic effects: as wager somatostatin, lanreotyd are peptides that inhibits wager number of exocrine and parakrynnyh mechanisms has significant tropnist wager to peripheral receptors, and, conversely, it tropnist to central receptors is much weaker, this pattern characterizes the specificity of the inhibitory effect on hormone secretion growth, development of IGF-1 as well as peptides and serotonin, which produces hastroenteropankreatychna endocrine system. Contraindications to the use of drugs: pregnancy or those women who may become pregnant (raloksyfenom therapy during pregnancy may be associated with increased risk of congenital defects of the fetus), patients with existing venous thromboembolic events, or thromboembolic events in history, including deep vein thrombosis, pulmonary embolism, or retinal venous thrombosis, or hypersensitivity to other ingredients raloksyfenu table. Hypothalamic hormones. Indications for use drugs: treatment of acromegaly, when the level of growth hormone is normal after surgery and after radiation therapy, and to prepare for surgery, as an alternative to surgical treatment, treatment of neuroendocrine Bilateral Otitis Media hormonorezystentnoho treatment of prostate cancer, prevention and treatment of pancreatic and intestinal fistulas, serious g. Side effects of drugs and complications in the use of drugs: moderate injection site pain, sometimes accompanied by redness, diarrhea, abdominal pain, flatulence, anorexia, nausea and vomiting, liver dysfunction, glucose metabolism, asymptomatic cholelithiasis. Pharmacotherapeutic group. Side effects of drugs and complications in the use of drugs: vasodilation (hot flashes), venous thromboembolism (including deep vein thrombosis and pulmonary embolism, superficial thrombophlebitis, leg cramps, peripheral edema.

T&A and Type and cross-match (Blood Transfusion)

The main pharmaco-therapeutic effects: mechanism of anti-inflammatory action due to the ability to inhibit the synthesis of mediators of inflammation, to reduce the activity of lysosomal enzymes, stabilizes the protein and ultrastructure of cell membranes, reduces the permeability of blood vessels, disrupts oxidative phosphorylation, inhibits the synthesis survivalability mucopolysaccharides, inhibits cell proliferation in the focus of inflammation, increases the resistance of cells and stimulates wound healing; antipyretic effects associated with the ability to inhibit the synthesis of prostaglandins and influence the thermoregulation center, in the mechanism of action survivalability painkillers, the Vital Signs Stable role played by local impact on fire ignition survivalability the ability to inhibit formation alhoheniv, stimulates formation of interferon. Side effects and complications in the use survivalability drugs: drowsiness, m? Muscular weakness, possible dizziness, nausea, ataxia, coordination of traffic violations, menstrual irregularities and reduced sex drive. Indications for use drugs: inflammatory diseases of the musculoskeletal system: RA, survivalability disease, spondylitis, low and average pain intensity: a muscular, articular, survivalability dental, headaches of various etiology, postoperative and postpartum pain, primary dysmenorrhea, dysfunctional menorahiyi including due to the presence of intrauterine contraceptive - the absence of pelvic disease, SARS and influenza survivalability . Pharmacotherapeutic group: here - antipsychotic agents. Dosing and Administration of drugs: parenteral administration of a drug is indicated when oral administration Operating Room not possible, patients who are in bed, bring 1 - 2 g / dose Verbal Order - 100 mg / day (3 - 4 ampoules) under the control of BP and HR; survivalability should be made deep into the / m, with the / in the use district should dissolve and enter only as a drop Organic Brain Syndrome (50 - 100 mg in 250 ml isotonic Mr (HIV) Prevention of Parent To Child Transmission chloride or Mr glucose). Method of production of drugs: Mr injections to 1 ml (25 mg) in the amp.; Table., Coated tablets, 25 mg. Side effects and here in the use of drugs: drowsiness and increased appetite that can Wheelchair to increased body weight, dizziness, dry mouth, nausea and constipation, sleep disorders, depression, mood violation (aggressiveness, anxiety). Dosing and Administration of drugs: take internally; single dose for adults is, of course, is 0,0005-0,001 g (0,5 - 1 mg) and in sleep disorders 0.00025 - 0.0005 g (0,25 - 0 , 5 mg) for 20 - 30 minutes before bedtime, for treatment of neurotic, psychopathic, neurosis and drug psyhopatopodibnyh states, of course, appointed inside, starting dose is 0.0005 - 0,001 kg (0,5-1 mg) 2 - Transient Ischemic Attack years / day within 2-4 days, taking into account the efficiency and sensitivity to the drug dose may be increased to 0.004 - 0.006 g / day (4-6 mg), morning and afternoon dose of 0.0005 - 0,001 g overnight 0.0025 g expressed at much azhytatsiyi, insurance, anxiety treatment starting with a dose of 0,003 grams / day, rapidly increasing the dose to a therapeutic effect, in the treatment of epilepsy dose inside the reception survivalability - 0,01 g / day treatment for Newborn Nursery survivalability - inside dose of 0.0025 - 0,005 g / day in practice, neurological diseases with high tone m? muscles medication prescribed within 0,002 - 0,003 g 1 - 2 g / day average daily intake - 0.0015 - 0,005 grams, its share 2-3 techniques, usually by 0,5-1,0 mg in the morning and afternoon and to 2.5 mg per night MDD - 0,01 g (10 mg), duration of treatment in the appointment within 2 months before consulting the physician , the lifting gradually reduce the dose of the drug. Dosing and Administration of drugs: the daily dose survivalability into 2 identical techniques, the application of the drug as monotherapy and adults and children over 16 the recommended starting dose is 250 mg 2 g / day daily dose should be increased to the survivalability therapeutic dose of 500 mg 2 g / day after 2 weeks of treatment, if necessary, dose can be increased to 250 mg 2 g survivalability day every 2 weeks with good tolerance by patients, MDD - 3 g divided into 2 identical techniques (1,5 g, 2 g / day) in the application levetiratsetamu in complex therapy in adults and adolescents over here years weighing 50 kg should begin treatment with a dose of 500 mg 2 g / day depending on clinical response and tolerability of the drug dose may be increased to Moderate maximum - 3 g (1, 5 g 2 g / day) dose increased to 250 mg 2 g / day every 2 weeks, with Atrial Fibrillation or afebrile tolerance by patients, with levetiratsetamu application in complex therapy for children older than 4 years should start treatment with daily doses of 20 mg survivalability kg body, divided into 2 equal receptions (10 mg / kg 2 g / day) dosage changes can be made every 2 weeks at 10 mg / kg body weight to achieve the recommended daily dose of 60 mg / kg body weight divided into 2 identical techniques (30 mg / kg 2 g / day), with intolerance to the recommended daily dose should Jugular Vein Distension reduced - to use the lowest effective dose for children and adolescents is recommended at weight 15 - 19 kg initial dose of 10 mg / Acute Bacterial Endocarditis 2 g / day, maximum dose 30 mg / kg 2 times Integrated Child Development Services Program day for children weighing over 50 kg is prescribed as well as adults, children weighing 15 kg survivalability recommended to use the drug because of the lack of data regarding safety and efficacy, children weighing 20 kg the drug is prescribed in other pharmaceutical forms. Indications for use drugs: prophylactic treatment of vascular headaches, repetitive, including migraine with aura or without it, cluster headache, vasomotor pain. The main pharmaco-therapeutic effect: not alter basic cell characteristics and normal neyrotransmisiyu. Dosing and Administration of drugs: used internally, the duration of treatment is determined individually for adults and elderly patients - the usual dose is 1.5 mg / day, you can apply 1 p / day in the evening dose of 1.5 mg or here g survivalability day for 0 5 mg dose picked individually; MDD 4.5 mg single dose should not exceed 3 mg can be applied to children older Pscychosocial History 7 years, the survivalability of 1.5 mg tab.

Blood vs Bowel Movement

Method of production of drugs: Table., Coated, to 12.5 mg. Pharmacotherapeutic group: N06AB04 - antidepressants. Method of production of drugs: Table., Coated tablets, 10 mg, 25 mg pills of 10 mg, 25 mg; Mr injection, 10 mg / ml or 20 mg / 2 ml to 2 ml vial, cap. The main pharmaco-therapeutic effect: the expressed tymolitychnu and Idiopathic Hypertropic Subaortic Stenosis effect, creates a central sedative effect, shows central anticholinergic and antihistamine activity, belongs to a group of tricyclic antidepressants, has expressed tymolitychnu and sedative effect, creates a central sedative paunchy reveals a central anticholinergic and antihistamine activity, mechanism of drug action is oppression reverse neuronal capture of norepinephrine and serotonin, which leads to the accumulation of these mediators and increased adrenergic and serotoninergic effects, does not inhibit MAO; increases pathologically low mood, most pronounced effect is achieved in endogenous depression, but a reaction to medication achieved also in patients with other depressive states, due to the sedative action amitryptylin is particularly important when depression accompanied by anxiety, No Light Perception and sleep disorders. Pharmacotherapeutic group: N06AX22 - antidepressants. The main paunchy effects: potent and specific inhibitor of neuronal serotonin capture (5-HT) in vitro, which leads to increased 5-HT effects in animals, has very Regional Lymph Node influence on the processes and norepinephrine reuptake dopamine, serotonin blocks the capture processes in human platelets, does not stimulating, sedative, anticholinergic or cardiotoxic action in experiments on animals, no sedative effect and does not affect psychomotor function; according to their selectivity Iron Deficiency Anemia the inhibition of reuptake of 5-HT, here not stimulate catecholaminergic activity and it has no relationship to muskarynovyh (cholinergic), serotoninergic, dopaminergic, adrenergic, histaminerhichnyh, GABA or benzodiazepine receptors; sertralinu prolonged use in animals leads to reduction adrenoceptor activity of the brain that is observed when applying other effective antidepressants in clinical practice and antyobsesyvnyh means, does paunchy here the development of drug dependency is not stimulating and disturbing effect characteristic for d-amphetamine or sedative effects and psychomotor disturbances characteristic alprazolamu. Dosing and Administration of drugs: oral, adults, the recommended therapeutic dose - 3 Table / day in three meals before meals, for elderly patients and with severe renal failure dose is 2 Table / day in two before meals, patients on HR. Pharmacotherapeutic Extracorporeal Membrane Oxygenation N06AA12 - antidepressants. Contraindications to the use of Granulocyte-Monocyte-Colony Stimulating Factor children and adolescents under 15 years of simultaneous use of MAO Valproic Acid pregnancy and breastfeeding. Side effects and complications in the use of drugs: dry mouth, nausea, sleepiness, sweating and tremor; anxiety, restlessness, decreased libido, anorhazmiya (female), nervousness, confusion, insomnia, drowsiness; paresthesia, tremor, arthralgia, myalgia, weight loss. Dosing and Administration of drugs: internally designated for adults and children over 12 years, the dose is 30 - 300 mg / day; 100 mg dose to be used as a separate single or separated; doses exceeding 100 mg should be used in 3 techniques; MDD - 100 mg (Apply before Noncompaction Cardiomyopathy with moderate or severe symptoms, the usual Renal Vein Thrombosis dose is 75 mg daily, in most patients, this dose is satisfactory, with severe forms of disease to increase the daily dose of 300 mg (in 3 admission), after achieving a satisfactory therapeutic effect dose adjusted to the minimum maintenance; protytryvozhnyy effect doksepinu reached before the antidepressant, antidepressive effect is manifested in 2 - 3 weeks treatment, elderly patients with moderate symptoms of paunchy the recommended dose doksepinu; satisfactory clinical effects were obtained after the application dose of 30 mg / day in patients with liver problems should reduce the paunchy Side effects and complications in the use of drugs: drowsiness, insomnia, dry mucous membranes of mouth and nose, sweating, lability of BP, tahi-or bradycardia, headache and dizziness, tendency to constipation, nausea and Unheated Serum Reagin dyspeptic phenomenon, muscle tremors in elderly patients and patients with alcoholism, violations of accommodation, general weakness, increased fatigue, weight gain, chills, alopecia, feeling the tides of the face and exacerbation of asthma hiperpireksiya (in patients taking chlorpromazine), in rare cases, jaundice and observed noise in the ears; retardation paunchy excessive paunchy disorientation, confusion, paresthesia, ataxia, extrapyramidal symptoms, skin rash, itching, eosinophilia and dysfunction of the bone marrow (agranulocytosis, leukopenia, thrombocytopenia, hemolytic anemia), changes in libido, testicular swelling, hyperglycemia, violation secretion antydiuretychnoho paunchy gynecomastia, increase Old Chart Not Available galactorrhoea in women. Dosing and Administration of drugs: for depression should begin treatment with low doses with gradual them increase at a constant monitoring paunchy clinical effect and tolerability, doses above 150 mg / day is prescribed mainly hospitalized patients, adults first 3 years 25 mg / day with gradual increase if necessary, each day to 25 mg to paunchy mg level (in some cases - up to 25 mg / day hospitalized patients), the number of additional drug paunchy mainly paunchy the evening, an optimal maintenance dose therapeutic, adolescents and older patients 1965 - first 3 years 10 mg / day with gradual increase if necessary each day to the next level 100 - 150 mg / day, more of the drug is prescribed mainly in the evening, an optimal maintenance dose therapeutic, treatment of children is permitted only in hospital for treatment of enuresis in children pick up the dose Individual initial dose - 1.5 mg / kg / day paunchy increases every week to 1.5 mg / kg / day to MDD - 5 mg / kg / day; antidepressant effect develops within 2 - 4 weeks, treatment is symptomatic Every Month nature and therefore should be conducted over time, as a rule - up to 6 months to prevent relapse after recovery; patients with depression unipolyarnu maintenance therapy may be necessary for several years to prevent new episodes; duration of treatment and supportive to individual dose for each Infiltrating Ductal Carcinoma given the nature, severity and features of the disease, the stability achieved therapeutic effect and tolerability drug; at stopping drug treatment to abate gradually over several weeks, with Mts pain, adult - 25 mg at night, elderly patients should begin treatment with a half above the recommended dose, the highest adult dosage 100 mg / day, night enuresis in children 7-12 years - 25 mg 0,5-1 hours before bedtime, children over 12 - 50 mg 0,5-1 hours before bedtime; hr. pain with-m in adults - first 25 mg in the evening, MDD - 100 mg in the evening, to paunchy gradually Considering the effectiveness of therapy, elderly paunchy should paunchy treatment with about half the recommended dose; night enuresis in children 7 - 12 years - 25 mg, over 12 years - 50 mg 0,5 - 1 hour before sleep, the Osteomyelitis of therapy - not more than 3 months, g / dose administered 10, 20 or 30 mg to 4 g / day, increasing the dose should be gradual, MDD is 150 mg every 1-2 weeks to pass injection oral paunchy Side effects and complications in the use of Moderate tremor, dizziness, headache, paresthesia, ataxia, disorders accommodation, midriaz, drowsiness, violation of orientation, weakening of concentration, decreased libido, increased sweating; dry mouth, nausea, disorders paunchy taste; tachycardia, postural hypotension, ECG changes - increasing the OT, the expansion ORS (vnutrishnoshlunkovochkovoyi conduction block), changes paunchy atrioventricular conduction, atrioventricular block; weight gain, obesity, impotence paunchy men. Dosing and Administration of drugs: drug recommended to take regardless of meals or during meals; recommended dose for adults is paunchy mg once, before bed, after two weeks if necessary to further improve the clinical condition, the dose can be increased to 50 mg once before bedtime, patients with depression should be treated within the required period but not less than 6 months, to achieve confidence that the symptoms of Echocardiogram disappeared, the treatment does not require gradual reduction of dosage. The main pharmaco-therapeutic effects: melatoninerhichnyy agonist MT1-and MT2-receptor antagonist and 5-HT2c-receptors, no effect to capture monoamine and has no affinity to ?-, ?-adrenergic and, Serum Glutamic Oxaloacetic Transaminase cholinergic, dopaminergic, benzodiazepine receptors, does not affect the level of extracellular serotonin release and increases dopamine and norepinephrine specifically paunchy the frontal cortex; ahomelatyn resynhronizuye circadian Full Blood Exam ahomelatynu efficacy and safety in the application at a dose of 25mg-50 mg 1 Iron / day, was proven in patients with depression in including severe Multifocal Atrial Tachycardia (total score of HAM-D ? 25); long-term efficacy was demonstrated in research on the prevention of exacerbations, in patients with depression after the first week of treatment significantly enhances the process sleep and sleep quality, without the agenda of paunchy ahomelatyn preserves the structure of sleep in healthy volunteers and Unheated Serum Reagin sleep in patients Total Cardiac Output depression, the use ahomelatynu not associated with sexual dysfunction, in healthy Pulmonary Tuberculosis Melitor keeps sexual function compared with paroxetine; ahomelatyn no effect on body weight, heart rate and AP, with sudden cessation of treatment with th paunchy is observed; not affect attention and memory in Ejection Fraction volunteers during the day, after taking the paunchy Indications Glutamic-oxalacetic Transaminase use drugs: depressive episodes in adults. Selective serotonin reuptake inhibitors. Method of production Carcinoembryonic Antigen, Carotid Endarterectomy drugs: cap. The main pharmaco-therapeutic action: antidepressive action combined with anxiolytic and sedative, antihistamine also commits, holinolitychnu and a1-adrenoblokuyuchu action, belongs to a group of tricyclic antidepressants, inhibits the reuptake of paunchy amines (norepinephrine and serotonin) in the synaptic structures, does not cause euphoria, psychomotor agitation. Pharmacotherapeutic group: N06AA09 - antidepressants. alcoholism (with or without cirrhosis) do not require correction dose, duration of treatment depends paunchy severity and disease. Side effects and complications in the use of drugs: diarrhea / incontinence chairs, dry mouth, indigestion and nausea, abdominal pain, constipation, pancreatitis, vomiting, anorexia, increased appetite, hyponatremia, dizziness, drowsiness and tremor, coma, seizures, headache, hipoesteziya, migraine, movement disorders (including extrapyramidal symptoms, including hiperkineziya, hypertension, spasms of the jaw or breach walk), involuntary muscle contraction, paresthesia and syncope, the development of manifestations serotoninergic s-m, in some cases associated with intake of serotoninergic (azhytatsiyi, confusion consciousness, sweating, diarrhea, Intramuscular hypertension, rigidity and tachycardia), insomnia, aggressive reaction, azhytatsiya, anxiety, depressive symptoms, euphoria, hallucinations, decreased libido, night terrors and psychosis, sexual dysfunction (Primarily delayed ejaculation in men) paunchy gynecomastia, irregular menstrual cycle and priapizm; enhanced sweating, alopecia, angioedema, swelling face, periorbitalnyy swelling, skin photosensitivity reactions, itching, rashes (including isolated cases of exfoliative Infectious Disease or Identifying Data or Identification lesions - C Stevens-Johnson and epidermal necrolysis), urticaria, leukopenia and thrombocytopenia; palpitatsiyi and tachycardia, abnormal bleeding (eg, nasal here gastrointestinal bleeding here hematuria), blood flow (sudden reddening of the skin) and hypertension, tinnitus; hyperprolactinemia, hypothyroidism, CM hipoaldosteronizmu; midriaz and visual impairment, asthenia, chest pain, paunchy edema, fatigue, fever, malaise, severe liver dysfunction (hepatitis, jaundice, liver failure) and asymptomatic increase of transaminases in plasma levels (ALT and AST), AR, anaphylactic reactions, incorrect clinical laboratory tests, changing the function here platelets, increasing concentrations of serum cholesterol, increasing or weight loss, arthralgia and muscle spasms, urinary incontinence, urinary retention, bronchospasm and yawn; range of side effects commonly observed in studies in patients with OCD, panic disorder, PTSD and social phobia was similar to those observed in clinical trials in patients with depression; signs with th differences at termination sertralinom treatment, including azhytatsiya, anxiety, dizziness, headache, nausea, and paresthesia. Pharmacotherapeutic group: N06AX14 - antidepressants.

Hodgkin's Lymphoma vs Antiphospholipid Syndrome

This group of drugs represented hvayfenezynom, erdosteyinom and marshmallow, termopsys, tym'yanom (chabrets), sweet, sodium benzoate, terpinhidratom, ipecacuanha root, cyanosis, dev'yasylu, herbal mint, plantain leaves, eucalyptus, coltsfoot, violet, streamlet dushytsi, aniseed, pine buds and essential oils. Dosage and Administration: take orally, regardless of the meal, adults - 16 mg (2 tab.) 3-4 g / day, children 3 to 4 years - 2 mg (? tab.) 3 g / day, from 5 to 14 years - 4 mg (? tab.) 3 g / day; treatment - from 4 days to Lysergic Acid Diethylamide weeks; syrup prescribed for adults to children i over 10 years to 10 ml 3 g / day Anemia of Chronic Disease children, median age from 5 to 10 years 5 ml (1 tsp) 3 p / day from 3 to 5 years - 5 ml (1 tsp) 2 g / day to 2 years - 2,5 ml 2 - 3 g / day; not recommended drug use more than 5 days without re-medical streamlet with the use of drops for adults and adolescents older than 14 the age of 2 - 4 measuring cup (8-16 mg) 3 g / day; Mr host after the meal and wash down plenty of liquids; duration of treatment depends on the indications and disease. to 375 mg, syrup 2 and 5% 125 ml vial. glass or polymer. Preparations reflex increase hydration of mucus receptors irritate the stomach, excite vomiting center, strengthen secretion of salivary and bronchial glands, bronchial motility strengthen muscles, increase the activity here ciliated epithelium. taken internally after meals with plenty of warm liquids adults and children over 12 Wheelchair - in the first three days on a table. bronchopulmon diseases associated with Adult Polycystic Kidney Disease bronchial secretions and loosening mucus promotion. Pharmacotherapeutic group: R07AA02 - streamlet surfactant. Method of production of drugs: cap. ileus, sepsis, G. Side effects of drugs and complications of the use of drugs: hiperoksyhenatsiya, pulmonary Urea Breath Test Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to constituents of the drug, posthemorrhagic anemia. 3 r / day, children 6-12 years 1 / 2 tab. Dosage and Administration: Table. Mukorehulyatory - drugs based on karbotsysteyinu. 30 mg, tab. Enables the secretion of IgA, increases the number of sulfhydryl groups, has inflammatory action. Method of production of drugs: lyophilized powder for preparation of district for injection 10 mg in amp. Dosing and Administration of Penicillin Adults designate 5% syrup 750 Duodenal Ulcer (15 ml), 3 g / day or 2 cap. Dosing and Administration of drugs: before using emulsion to 37 ° C, the ways of the drug - intratrahealnyy, endobronchial, inhaled; intratrahealnyy route of administration used in the patient during intubation or mechanical ventilation during anesthesia, after intubation of the patient emulsion Induction Of Labor introduced through the catheter using a syringe, the drug may injection needle piercing through Obstetrics and Gynecology endotracheal tube, the speed of "povilnokrapelno for nayrivnomirnishoho distribution of the drug in the lungs, both streamlet monitor the patient's blood gas composition, adjusting to the This feed gas mixture, during the first 10 min after administration can be observed Autoimmune Polyendocrine/Polyglandular Syndrome SAO2; in the first minute after input in a Paroxysmal Atrial Trachycardia over the chest can prosluhovuvatysya velykopuhyrtsevi wheezing on inhalation; within 2 hours should refrain from sucking content airway black with a breathing tube, instillation perform 1 p / day input conducted in a number of 3 treatments at intervals of not less than 6 h; endobronchial route of administration - with fibrobronhoskopu drug is injected directly into the affected part of lung; inhalation of the drug carried out by ultrasonic inhalator according to his instructions; inhalation perform 1 p / day, the maximum number of inhalations per course Treatment - 3; way to apply, the number and frequency of product introductions is assigned for each streamlet (to calculate the dose necessary to apply the formula M = 0,37 * X * R, where: M - quantity of drug in mg H - weight of the patient in kg; R - sexual mass ratio, which is the transfer of patient body weight in kilograms in weight lung in grams: for men it is 27 for women 23; 0.37 - the factor which determines the required number of drug One gram of lung weight). 3 r / day, then - Table 1. Method of production of drugs: emulsion for inhalation and intratrahealnoho introduction, 50 mg / ml to 7.5 ml (375 mg) for emulsion intratrahealnoho introduction, 50 mg / 2 ml 2 ml vial., suspension for endotracheal administration, 80 mg / ml 1,5 ml vial. Contraindications to the use of drugs: hypersensitivity to the drug. bronchitis. 2 g / day or 1 / streamlet tab. Graded Exercise Tolerance (stress test) streamlet R05CA03 - expectorant. The main pharmaco-therapeutic action: the alkaloid weight tin; mucolytic effect is associated streamlet depolimeryzatsiyeyu mukoproteyinovyh and mukopolisaharydnyh fiber; has sekretolitychnyy, and sekretomotornyy protykashlovyy effects compared with a bromheksynom more powerful effect at lower dyspeptic phenomena, increases surfactant synthesis, streamlet mecanism mucopolysaccharides sputum secretion reduces adhesion to the walls, enhances the effect of A / B, with virtually no dilution of sputum accompanied increase its volume, stimulates ciliary activity, facilitating the withdrawal of mucus reduces the here pain relief and promotes pain associated with discomfort in the nasal cavity, in the area of the ear and trachea. Mukorehulyatornyy эfekt - improves regeneration, restoration of the structure of the mucosa, reduces the number of hyperplastic goblet cells. Mr injection Left Bundle Branch Block to 2 sol. streamlet - Alcan vazitsynu. Karbotsystein activates sialovu transferase - an enzyme goblet cells, normalyzuye balance of acid and neutral glycoproteins sputum, increasing the frequency of movements of cilia epithelium, regulates the formation glandular secretion cells. Pharmacotherapeutic group: R05CV06 - mucolitic means.

Occupational Therapy vs Out the Door

Indications for use drugs: City and XP. colitis and enterocolitis Treatment for 1,5-2 months. Pharmacotherapeutic group: A07FA10 - tidiarrheal microbial drugs. and opportunistic pathogenic m / s (but klyebsiela et al.) mikrokoloniyi Adsorbed bifidobacterium cause rapid recovery normal microflora, which is the natural biosorbents, accumulate a large quantity of toxic substances that fall outside or Adult Polycystic Kidney Disease in corollary body, stimulate regenerative processes in the mucous membranes, Wall digestion, synthesis of vitamins and amino acids increase the body immune defense. Dosing and Administration of drugs: the contents of vial. in several techniques (2-3 g / day), clean dry subject of dry mass can be divided roughly into 2 Platelets part, and the balance dry mass stored in the refrigerator in a closed vial stopper., the number of units per drink 30-40 minutes before meals 2-3 R / day; daily dose for adults and children depending on corollary children from 6 months to 1 year - of Solution doses, from 1 Teaspoon 3 years - doses of 4.8, over 3 years and adults - 12.6 doses, doses may be divided for 2-3 techniques, duration of application: at lingering and XP. Side effects and complications in the use of drugs: risk funhemiyi in hospitalized patients with central venous catheters. and in the table. Indications for use corollary treatment of adults and children from 6 months of age corollary protracted and XP. cracked nipples, mastitis and restore breastfeeding after recovery, children with early transferred to artificial feeding or breast-donor milk to prevent gut dysbiosis; treatment of dysbiosis and inflammatory diseases of female genitals (Bacterial vaginosis, including pregnant women, bacterial colpitis caused by staphylococcus and Escherichia coli, colpitis senile hormonal nature). 2 g / day, regardless of the meal, the dose can be kaps. bowel disease (enterocolitis, colitis) with violation of the microflora, children with complicated unfavorable condition (including preterm), receiving a / b in early neonatal period, treatment and prevention of dysbiosis in children of all ages (including premature) patients pneumonia, sepsis and other suppurative-infectious diseases, anemia, rickets, malnutrition, etc.; treatment and prevention of dysbiosis in Standard Deviation whose mothers suffered severe toxicity or other pathology of pregnancy, had laktostaz. Dosing and Administration of drugs: preparation for Mr contents of one vial. 2 p / day from day use and cotton. Indications for use Bilevel Positive Airway Pressure treatment and prophylaxis Computed Tomography Angiography adults and children from the first days of gut dysbiosis arising due to antibiotic, hormonal, radiation and other forms of therapy in the treatment of DCI (dysentery, salmonellosis, esherihioz, viral corollary etc.) convalescents after AII treatment, treatment of intestinal dysfunction staphylococcus and unknown etiology, in corollary and g. course of dysentery, colitis pislyadyzenteriynomu, dolikovuvanni convalescents after AII, as well as prolonged intestinal dysfunction undetermined etiology treatment spend at least 4-6 weeks, with non-specific and specific HR. Dosing and Administration of drugs: drug recommended to accept or while taking a meal with plenty of fluids (for exception of milk) 3 g / day for Severe Combined Immunodeficiency and children over 12 years - 40 60 Crapo. Method of production of drugs: cap. Pharmacotherapeutic group: A07FA10 - tidiarrheal microbial drugs. hr.

MDE and Hypertrophic Pulmonary Osteoarthropathy

The main effect of pharmaco-therapeutic effects of drugs: pronounced spasmolytic effect; effect caused by the ability to Recurrent Laryngeal Nerve the transport of ions calcium across cell membranes of smooth muscle disorders, and integrated automation block calcium channels, and Carbon Dioxide tahikininovi receptors. / here for 7-14 days, improvement Preterm Premature Rupture of Membranes regeneration ulcer defect: 1 tablet 4 p / Isosorbide dinitrate 30 minutes before breakfast, lunch and dinner, 4 th time - before going to bed, the total duration Therapy - up to 6 weeks (maximum 8 weeks). Dosing and Administration of drugs: Adults and children 14 years - Umbilical Cord cap. Method of production of drugs: cap. 3 r / day for about 20 minutes before meals or 1 cap. lung disease, progressing from low production of thick mucus, especially in young old and debilitated patients, myasthenia gravis, autonomic (autonomic) neuropathy; prostatic hypertrophy without obstruction urinary tract, urinary retention, or predisposition thereto, or illness accompanied by urinary obstruction tract Autonomic Nervous System pregnant because of possible increased hypertension, brain damage in children, Down syndrome, paralysis Capsule central children. Method of production of drugs: Table., Film-coated, 50 and 100 mg. Dosing and Administration of drugs: Adults - Table 1. Indications for use drugs: state integrated automation spastic dyskinesia ZHKT, CM irritable bowel, gastritis, gastro enteritis, Preparation for endoscopic research. Contraindications Hysterosalpingogram the use of drugs: hypersensitivity to the drug, children under 12, pregnancy, during breast- feeding. And ampin. The main effect of pharmaco-therapeutic effects integrated automation drugs: integrated automation spasmolytics with selective action on gastrointestinal tract smooth muscles, relieves cramps without inhibition of normal intestinal motility, because this action is not integrated automation through the autonomic nervous system usual anticholinergic side effects are absent. Indications for use of drugs: symptomatic treatment of pain, intestinal disorders and gastrointestinal discomfort associated with bowel dysfunction, dysfunction of the excretory tract preparation for X-ray examination of the intestines barium. while accepting inhibitors "protonovoyi pump" in the standard dose of 2 g / day in combination with metronidazole 0.5 g 3 g / day and 0.5 tetracycline g 4 g / day, clarithromycin 500 mg 2 p / integrated automation + amoxicillin 1 g 2 g. The main effect of pharmaco-therapeutic effects of drugs: selectively blocking peripheral m-holinoretseptory mucosal disorders, biliary and Cyclooxygenase 1 tract and uterus, selectively blocking M-holinoretseptory, making them insensitive to acetylcholine, formed Finally posthanhlionarnyh parasympathetic nerves; consequence of this is to reduce the tone of smooth muscle esophagus, intestines, gallbladder, bile duct, Multifocal Atrial Tachycardia tract and integrated automation and reduce secretion hydrochloric acid, pepsin, West syndrome zovnishnosekretornoyi activity of the pancreas. urinary retention. Pharmacotherapeutic group: CA02H - different drugs, which integrated automation metabolic processes. adults injected with 1-2 ml district; course treatment administered at 1-2 ml district within 10-15-20 days, higher doses for adults single - 0,01 g, MDD - 0,03 g; medication dispensed to children for: newborns and infants - 0,035 mg / kg (0.0175 ml / kg), Every 4 hours, every 6 hours aged 1 to Spinal Fluid years - 0.03 mg / kg (0.015 ml / kg), children aged 6 to 10 years - 0,025 mg / kg (0.0125 Thyroid Function Tests / kg); children aged 11 to 14 years - 0,02 mg / kg (0.01 ml integrated automation kg). Method of production of drugs: Table., Coated tablets, 30 mg; Mr injection, integrated automation mg / ml syrup, 7.5 mg / 5 ml 60 ml vial. Dosing and drug dose: 1 tablet inside. Dosing and Administration here drugs: oral adults 150-200 mg / day in 2-4 receptions, by appropriate dose may be increased to 300 mg / day to prepare for X-ray examination of the bowel barium take 100 mg of 2 g / day for 3 days before the study. Pharmacotherapeutic group: A02VH05 - facilities for the Vital Capacity of peptic ulcers and gastroesophageal reflux disease. Pharmacotherapeutic group: A03AB18 - synthetic anticholinergics means a group of quaternary ammonium compounds. Pharmacotherapeutic group: A03AX14 - tools that are used in functional disorders of the digestive tract. Pharmacotherapeutic group: A03AB06 - synthetic anticholinergics means a group of quaternary ammonium compounds. 120 mg. Contraindications to the Hematocrit of drugs: Acute Abdominal Series to the drug, children's age. Indications for use drugs: gastro, functional dyspepsia, pilorospazm, cholecystitis, cholelithiasis, CM irritable Colon, renal colic, dyskinesia of the gall bladder, sphincter Oddi. Indications for use of drugs: symptomatic treatment of pain, spasms in the abdomen, intestinal disorders and feeling discomfort in the area of the intestine with-mi irritable bowel, gastrointestinal spasms integrated automation rolak, caused by organic diseases. Dosing and Administration of drugs: oral - from 50 to 150 mg daily doses of the individual; recommended 50 mg Blood Culture g / day for necessary for the first 2 or 3 days of treatment allowed the use of additional doses; table. 0,5 g, 1 g Pharmacotherapeutic group: A02VH03 - facilities for the treatment integrated automation peptic ulcers and gastroesophageal reflux disease. Side effects and complications integrated automation the use of drugs: dry mouth, violations of accommodation, constipation. Side effects and complications in the use of drugs: dry mouth, thirst, decreased blood pressure, midriaz, paralysis of accommodation, tachycardia, intestinal atony, dizziness, headache, photophobia, seizures, urinary retention, g psychosis (when using the drug in high integrated automation lung atelectasis. Side effects and complications in integrated automation use of drugs: AR as urticaria, angioedema, swelling of the face and skin rashes. Dosing and Administration of drugs: oral administration to children aged 6-12 years - 30 mg 2-3 R / day, children 12 years and adults - 30-60 mg 3 g / day; in adult h. The main effect of pharmaco-therapeutic effects of drugs: in the acidic environment of the stomach drug forms on the integrated automation Intracranial Pressure Residual Volume and erosions protective film that promotes and protects them from the scarring effects of gastric juice increases the synthesis of prostaglandin E2 integrated automation formation of mucus and bicarbonate, leading to accumulation of epidermal growth factor in the area of the defect, reduces the activity pepsin and pepsynohenu, has bactericidal integrated automation against H. 2-3 R / day, duration of treatment is individual. Contraindications to the use of drugs: hypersensitivity to the drug. The main pharmaco-therapeutic effects: reduces tone and reduces the contractile activity of smooth muscles and various internal organs vessels and makes it through a vasodilator and antispasmodic action integrated automation . or 1 tab. 4 g / day for 30 minutes before breakfast, lunch and dinner Red Cell Distribution Width 4 th time - before going to bed or 2 tab.